Phathom Pharmaceuticals’ VOQUEZNA Added to Express Scripts Formularies
Company Announcements

Phathom Pharmaceuticals’ VOQUEZNA Added to Express Scripts Formularies

Phathom Pharmaceuticals (PHAT) has released an update.

Phathom Pharmaceuticals, Inc. has made strides in the healthcare market as their drug VOQUEZNA gains immediate inclusion on Express Scripts’ national formularies for commercial plans. This significant development simplifies patient access to VOQUEZNA by allowing it to be prescribed directly after a generic proton pump inhibitor, streamlining treatment options for those in need.

For further insights into PHAT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskPhathom Pharmaceuticals Reports Significant Revenue Growth
TheFlyPhathom Pharmaceuticals reports Q3 EPS ($1.32), consensus ($1.49)
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App